Aclaris Therapeutics, Inc.

NasdaqGS:ACRS Stock Report

Market Cap: US$239.7m

Aclaris Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:ACRS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
19 Nov 24BuyUS$1,499,999Anand MehraIndividual666,666US$2.25
05 Aug 24BuyUS$472,757BML Capital Management, LLCCompany373,569US$1.29
31 Jul 24BuyUS$359,010BML Capital Management, LLCCompany273,730US$1.33
22 Jul 24BuyUS$201,808BML Capital Management, LLCCompany154,722US$1.33
05 Jul 24BuyUS$405,894BML Capital Management, LLCCompany352,397US$1.16
01 Jul 24BuyUS$1,742,075BML Capital Management, LLCCompany1,543,434US$1.15
18 Jun 24BuyUS$628,206BML Capital Management, LLCCompany545,000US$1.17
13 Jun 24BuyUS$1,781,897BML Capital Management, LLCCompany1,611,200US$1.15
04 Mar 24BuyUS$17,955Andrew Kenneth PowellIndividual14,500US$1.25

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ACRS?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders2,830,2192.64%
VC/PE Firms8,888,8888.31%
General Public15,599,72214.6%
Hedge Funds30,081,61328.1%
Institutions49,618,29346.4%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 51.1%.

Top Shareholders

Top 25 shareholders own 73.28% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
13.3%
BML Capital Management, LLC
14,250,000US$31.9m0%19.52%
9%
Adage Capital Management, L.P.
9,627,304US$21.6m0%0.04%
8.31%
Vivo Capital, LLC
8,888,888US$19.9m0%2.01%
5.8%
Rock Springs Capital Management LP
6,204,309US$13.9m125%0.52%
4.36%
RA Capital Management, L.P.
4,666,667US$10.5m0%0.14%
4.04%
The Vanguard Group, Inc.
4,325,263US$9.7m-7.69%no data
3.08%
D. E. Shaw & Co., L.P.
3,293,625US$7.4m-2.32%0.01%
2.62%
Janus Henderson Group plc
2,799,759US$6.3m0%no data
2.46%
Marshall Wace LLP
2,634,065US$5.9m0%0.01%
2.23%
Samsara BioCapital LLC
2,385,060US$5.3m243%1.05%
2.12%
Decheng Capital LLC
2,266,667US$5.1m0%1.29%
2.08%
Logos Global Management, L.P.
2,222,222US$5.0m0%0.65%
1.83%
Millennium Management LLC
1,959,047US$4.4m-34.8%no data
1.63%
Acadian Asset Management LLC
1,744,147US$3.9m-16.1%0.01%
1.36%
Neal Walker
1,460,718US$3.3m1.89%no data
1.18%
BlackRock, Inc.
1,257,779US$2.8m-26.5%no data
1%
Morgan Stanley, Investment Banking and Brokerage Investments
1,068,805US$2.4m124%no data
0.95%
Aldebaran Capital, LLC
1,016,958US$2.3m-2.51%2.18%
0.91%
Two Sigma Advisers, LP
977,400US$2.2m-24.9%no data
0.9%
PEH Wertpapier AG
963,544US$2.2m0%0.15%
0.86%
Deutsche Asset & Wealth Management
923,313US$2.1m0%no data
0.85%
Connor, Clark & Lunn Investment Management Ltd.
908,819US$2.0m173%0.01%
0.83%
Monashee Investment Management, LLC
888,888US$2.0m0%0.27%
0.79%
Renaissance Technologies LLC
850,519US$1.9m-38%no data
0.78%
Two Sigma Investments, LP
839,270US$1.9m-7.56%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/23 09:48
End of Day Share Price 2025/02/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aclaris Therapeutics, Inc. is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julian HarrisonBTIG
Louise ChenCantor Fitzgerald & Co.
Gavin Clark-GartnerEvercore ISI